The 5-Second Trick For Imipenem
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage various intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important demo aims were To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyosi